<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02007863</url>
  </required_header>
  <id_info>
    <org_study_id>20080774</org_study_id>
    <nct_id>NCT02007863</nct_id>
  </id_info>
  <brief_title>Umbilical Cord Blood (UCB) Transplantation in Pediatric Patients With High Risk Leukemia and Myelodysplasia</brief_title>
  <official_title>Treatment Protocol: Umbilical Cord Blood (UCB) Transplantation in Pediatric Patients With High Risk Leukemia and Myelodysplasia Using Conditioning Regimen Without Radiation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Miami</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Miami</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Unrelated Cord Blood (UCB) transplant in children is a viable stem cell transplant modality
      for patients with leukemia and myelodysplasia. UCB is now considered &quot;Standard Of Care&quot; in
      cases where a suitable living bone marrow donor is not available. The survival of UCB is
      similar to Matched Unrelated Marrow Transplant. This study is considered &quot;Research&quot; since UCB
      is not a licensed product and requires investigational new drug (IND). THERE ARE NO SPECIFIC
      RESEARCH QUESTIONS IN THIS PROTOCOL. This protocol merely provides UCB as a stem cell
      treatment modality to pediatric patients who may require it after a conditioning regimen that
      excludes Total Body Irradiation.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The preparative regimen will consist of:

        -  Fludarabine: 25 mg/m2/day IV x 5 doses on Days -13, to -9

        -  Busulfan 1mg/kg IV every 6 hrs x 16 doses on Days -8 to -5

        -  Melphalan 45 mg/m2/day IV x 3 doses on days -4 to -2

        -  ATGAM 30mg/kg/day x 3 doses on Days -3 to -1

        -  Day 0 will be the day of the UCB Transplant

        -  The graft-versus-host-disease (GVHD) prophylaxis will be Cyclosporin A to maintain level
           200-400 beginning on Day -3, through 200-400. Solumedrol at 1mg/kg/day on Day 1 until
           D+4, then solumedrol 2mg/kg/day until Day +19 or till absolute neutrophil count (ANC)
           reaches 500/mm2, then taper by 0.2 mg/kg/week.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2008</start_date>
  <completion_date type="Actual">June 2014</completion_date>
  <primary_completion_date type="Actual">June 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Successful Unrelated Cord Blood (UCB) Transplants</measure>
    <time_frame>2 Years</time_frame>
    <description>The number of patients who received successful UCB transplants as evidenced by absolute neutrophil recovery.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">2</enrollment>
  <condition>Leukemia</condition>
  <condition>Myelodysplasia</condition>
  <condition>Acute Lymphocytic Leukemia</condition>
  <condition>Acute Myelogenous Leukemia</condition>
  <arm_group>
    <arm_group_label>Umbilical Cord Blood + Chemotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Umbilical Cord Blood transfusion + Chemotherapy (Fludarabine + Busulfan + Melphalan)</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Umbilical Cord Blood Transfusion</intervention_name>
    <description>Following the administration of the preparative therapy, all subjects will undergo UCB transplantation. Umbilical Cord Blood Transfusion will occur on Day 0</description>
    <arm_group_label>Umbilical Cord Blood + Chemotherapy</arm_group_label>
    <other_name>UCB</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fludarabine</intervention_name>
    <description>Fludarabine 25 mg/m2/day will be administered over 30-60 minutes intravenous infusion on Days -13 through -9 for a total of 5 doses. Fludarabine will not be dose adjusted for body weight.</description>
    <arm_group_label>Umbilical Cord Blood + Chemotherapy</arm_group_label>
    <other_name>Fludara</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Busulfan</intervention_name>
    <description>Busulfan IV (Busulfex) will be administered IV every 6 hours on days -8 through -5 for a total of 16 doses. Seizure prophylaxis prior to first dose of busulfan till Day -3 will be administered.</description>
    <arm_group_label>Umbilical Cord Blood + Chemotherapy</arm_group_label>
    <other_name>Busulfex</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Melphalan</intervention_name>
    <description>Melphalan 45 mg/m2/day will be administered over 60 minutes intravenous infusion on Days -4 through -2 for a total of 3 doses.</description>
    <arm_group_label>Umbilical Cord Blood + Chemotherapy</arm_group_label>
    <other_name>Alkeran</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients must be up to 21 years of age

          -  Patients cannot receive total body irradiation (TBI) because of:

               -  Young age - &lt; 2 years at diagnosis of leukemia resulting in an age &lt; 4 years at
                  transplantation (due to risk of severe growth retardation and brain damage).

               -  Inability to tolerate TBI because of prior radiation or organ toxicity.

               -  Refractory/multiply relapsed leukemia, for which a traditional
                  TBI/cyclophosphamide regimen would unlikely lead to a successful outcome.

          -  Patients must have a partially human leukocyte antigen (HLA)-matched UCB unit. Unit
             must be HLA-matched minimally at 4 of 6 HLA-A and B (at intermediate resolution by
             molecular typing) and DRB1 (at high resolution by molecular typing) loci with the
             patient. The unit must deliver a pre-cryopreserved nucleated cell dose of at least 2.5
             x 10^7 per kilogram.

          -  Acute myelogenous leukemia (AML) at the following stages:

               -  High risk first complete remission (CR1), defined as:

                    -  Having preceding myelodysplasia (MDS)

                    -  High risk cytogenetics (High-risk cytogenetics: del (5q) -5, -7, abn (3q), t
                       (6;9) complex karyotype (&gt;= 5 abnormalities)

                    -  Requiring &gt; 2 cycles chemotherapy to obtain CR;

               -  Second or greater CR.

               -  First relapse with &lt; 25% blasts in bone marrow.

          -  Patients with therapy-related AML whose prior malignancy has been in remission for at
             least 12 months.

          -  Acute lymphocytic leukemia (ALL) at the following stages:

          -  High risk first remission, defined as:

               1. Ph+ ALL; or,

               2. Myeloid/lymphoid leukemia (MLL) rearrangement with slow early response [defined
                  as having M2 (5-25% blasts) or M3 (&gt;25% blasts on bone marrow examination on Day
                  14 of induction therapy)]; or,

               3. Hypodiploidy (&lt; 44 chromosomes or DNA index &lt; 0.81); or,

               4. End of induction M3 bone marrow; or,

               5. End of induction M2 with M2-3 at Day 42.

          -  High risk second remission, defined as:

               1. Bone marrow relapse &lt; 36 months from induction; or,

               2. T-lineage relapse at any time; or,

               3. Very early isolated central nervous system (CNS) relapse (6 months from
                  diagnosis); or,

               4. Slow reinduction (M2-3 at Day 28) after relapse at any time.

          -  Any third or subsequent CR.

          -  Biphenotypic or undifferentiated leukemia in any CR or if in 1st relapse must have &lt;
             25% blasts in bone marrow (BM).

          -  MDS at any stage.

          -  Chronic myelogenous leukemia (CML) in chronic or accelerated phase.

          -  All patients with evidence of CNS leukemia must be treated and be in CNS CR to be
             eligible for study.

          -  Patients ≥ 16 years old must have a Karnofsky score ≥ 70% and patients &lt; 16 years old
             must have a Lansky score ≥ 70%.

          -  Signed informed consent.

          -  Patients with adequate physical function as measured by:

               1. Cardiac: Left ventricular ejection fraction at rest must be &gt; 40%, or shortening
                  fraction &gt; 26%

               2. Hepatic: Bilirubin ≤ 2.5 mg/dL; and alanine transaminase (ALT), aspartate
                  transaminase (AST) and Alkaline Phosphatase ≤ 5 x upper limit of normal (ULN)

               3. Renal: Serum creatinine within normal range for age, or if serum creatinine
                  outside normal range for age, then renal function (creatinine clearance or GFR) &gt;
                  70 mL/min/1.73 m2.

               4. Pulmonary: Diffusing capacity of the lungs for carbon monoxide (DLCO), Forced
                  expiratory volume in 1 second (FEV1), Forced vital capacity (FVC) (diffusion
                  capacity) &gt; 50% of predicted (corrected for hemoglobin); if unable to perform
                  pulmonary function tests, then O2 saturation &gt; 92% of room air.

        Exclusion Criteria:

          -  Pregnant (B-positive HCG) or breastfeeding.

          -  Evidence of HIV infection or HIV positive serology.

          -  Current uncontrolled bacterial, viral or fungal infection (currently taking medication
             and progression of clinical symptoms).

          -  Autologous transplant &lt; 6 months prior to enrollment.

          -  Prior autologous transplant for the disease for which the UCB transplant will be
             performed.

          -  Allogeneic hematopoietic stem cell transplant &lt; 6 months prior to enrollment.

          -  Active malignancy other than the one for which the UCB transplant is being performed
             within 12 months of enrollment

          -  Active CNS leukemia.

          -  Requirement of supplemental oxygen.

          -  HLA-matched related donor able to donate.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>21 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Martin Andreasky, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Miami</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Jackson Memorial Hospital</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Miami Sylvester Comprehensive Cancer Center</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 3, 2013</study_first_submitted>
  <study_first_submitted_qc>December 6, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 11, 2013</study_first_posted>
  <results_first_submitted>July 1, 2015</results_first_submitted>
  <results_first_submitted_qc>November 20, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">December 28, 2015</results_first_posted>
  <last_update_submitted>November 20, 2015</last_update_submitted>
  <last_update_submitted_qc>November 20, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 28, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Miami</investigator_affiliation>
    <investigator_full_name>Martin Andreansky</investigator_full_name>
    <investigator_title>Associate Professor of Clinical</investigator_title>
  </responsible_party>
  <keyword>Leukemia</keyword>
  <keyword>Myelodysplasia</keyword>
  <keyword>Acute lymphocytic leukemia</keyword>
  <keyword>ALL</keyword>
  <keyword>Acute myelogenous leukemia</keyword>
  <keyword>AML</keyword>
  <keyword>Pediatric</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
    <mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Preleukemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fludarabine</mesh_term>
    <mesh_term>Fludarabine phosphate</mesh_term>
    <mesh_term>Melphalan</mesh_term>
    <mesh_term>Busulfan</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Umbilical Cord Blood + Chemotherapy</title>
          <description>Umbilical Cord Blood Transfusion: Following the administration of the preparative therapy, all subjects will undergo UCB transplantation. Umbilical Cord Blood Transfusion will occur on Day 0
Fludarabine: Fludarabine 25 mg/m2/day will be administered over 30-60 minutes intravenous infusion on Days –13 through –9 for a total of 5 doses. Fludarabine will not be dose adjusted for body weight.
Busulfan: Busulfan IV (Busulfex) will be administered IV every 6 hours on days -8 through -5 for a total of 16 doses. Seizure prophylaxis prior to first dose of busulfan till Day -3 will be administered.
Melphalan: Melphalan 45 mg/m2/day will be administered over 60 minutes intravenous infusion on Days –4 through –2 for a total of 3 doses.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Umbilical Cord Blood + Chemotherapy</title>
          <description>Umbilical Cord Blood Transfusion: Following the administration of the preparative therapy, all subjects will undergo UCB transplantation. Umbilical Cord Blood Transfusion will occur on Day 0
Fludarabine: Fludarabine 25 mg/m2/day will be administered over 30-60 minutes intravenous infusion on Days –13 through –9 for a total of 5 doses. Fludarabine will not be dose adjusted for body weight.
Busulfan: Busulfan IV (Busulfex) will be administered IV every 6 hours on days -8 through -5 for a total of 16 doses. Seizure prophylaxis prior to first dose of busulfan till Day -3 will be administered.
Melphalan: Melphalan 45 mg/m2/day will be administered over 60 minutes intravenous infusion on Days –4 through –2 for a total of 3 doses.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="2"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Successful Unrelated Cord Blood (UCB) Transplants</title>
        <description>The number of patients who received successful UCB transplants as evidenced by absolute neutrophil recovery.</description>
        <time_frame>2 Years</time_frame>
        <population>THERE ARE NO SPECIFIC RESEARCH QUESTIONS IN THIS PROTOCOL. This protocol merely provides UCB as a stem cell treatment modality to pediatric patients who may require it after a conditioning regimen that excludes Total Body Irradiation.Unrelated Cord Blood (UCB) transplant</population>
        <group_list>
          <group group_id="O1">
            <title>Umbilical Cord Blood + Chemotherapy</title>
            <description>Umbilical Cord Blood Transfusion: Following the administration of the preparative therapy, all subjects will undergo UCB transplantation. Umbilical Cord Blood Transfusion will occur on Day 0
Fludarabine: Fludarabine 25 mg/m2/day will be administered over 30-60 minutes intravenous infusion on Days –13 through –9 for a total of 5 doses. Fludarabine will not be dose adjusted for body weight.
Busulfan: Busulfan IV (Busulfex) will be administered IV every 6 hours on days -8 through -5 for a total of 16 doses. Seizure prophylaxis prior to first dose of busulfan till Day -3 will be administered.
Melphalan: Melphalan 45 mg/m2/day will be administered over 60 minutes intravenous infusion on Days –4 through –2 for a total of 3 doses.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Successful Unrelated Cord Blood (UCB) Transplants</title>
          <description>The number of patients who received successful UCB transplants as evidenced by absolute neutrophil recovery.</description>
          <population>THERE ARE NO SPECIFIC RESEARCH QUESTIONS IN THIS PROTOCOL. This protocol merely provides UCB as a stem cell treatment modality to pediatric patients who may require it after a conditioning regimen that excludes Total Body Irradiation.Unrelated Cord Blood (UCB) transplant</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Umbilical Cord Blood + Chemotherapy</title>
          <description>Umbilical Cord Blood Transfusion: Following the administration of the preparative therapy, all subjects will undergo UCB transplantation. Umbilical Cord Blood Transfusion will occur on Day 0
Fludarabine: Fludarabine 25 mg/m2/day will be administered over 30-60 minutes intravenous infusion on Days –13 through –9 for a total of 5 doses. Fludarabine will not be dose adjusted for body weight.
Busulfan: Busulfan IV (Busulfex) will be administered IV every 6 hours on days -8 through -5 for a total of 16 doses. Seizure prophylaxis prior to first dose of busulfan till Day -3 will be administered.
Melphalan: Melphalan 45 mg/m2/day will be administered over 60 minutes intravenous infusion on Days –4 through –2 for a total of 3 doses.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>THERE ARE NO SPECIFIC RESEARCH QUESTIONS IN THIS PROTOCOL. This protocol merely provides UCB as a stem cell treatment modality to pediatric patients who may require it after a conditioning regimen that excludes Total Body Irradiation.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Martin Andreansky MD</name_or_title>
      <organization>University of Miami</organization>
      <phone>305-243-0850</phone>
      <email>mandreansky@med.miami.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

